Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics (PRQR) Operating Leases (2017 - 2025)

ProQR Therapeutics' Operating Leases history spans 6 years, with the latest figure at $11.1 million for Q4 2025.

  • On a quarterly basis, Operating Leases fell 6.03% to $11.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $11.1 million, a 6.03% decrease, with the full-year FY2025 number at $11.1 million, down 6.03% from a year prior.
  • Operating Leases hit $11.1 million in Q4 2025 for ProQR Therapeutics, down from $11.8 million in the prior quarter.
  • Over the last five years, Operating Leases for PRQR hit a ceiling of $18.6 million in Q2 2021 and a floor of $18611.0 in Q1 2021.
  • Historically, Operating Leases has averaged $14.0 million across 5 years, with a median of $14.9 million in 2023.
  • Biggest five-year swings in Operating Leases: soared 86630.68% in 2022 and later fell 20.51% in 2024.
  • Tracing PRQR's Operating Leases over 5 years: stood at $16.9 million in 2021, then decreased by 16.47% to $14.1 million in 2022, then rose by 5.57% to $14.9 million in 2023, then fell by 20.51% to $11.8 million in 2024, then decreased by 6.03% to $11.1 million in 2025.
  • Business Quant data shows Operating Leases for PRQR at $11.1 million in Q4 2025, $11.8 million in Q4 2024, and $14.9 million in Q4 2023.